diethyl 2-{4-[2-(4-methylphenyl)-5-(trifluoromethyl)oxazol-4-yl]butyl}malonate | 1365270-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: diethyl 2-{4-[2-(4-methylphenyl)-5-(trifluoromethyl)oxazol-4-yl]butyl}malonate
• 英文别名: Diethyl 2-[4-[2-(4-methylphenyl)-5-(trifluoromethyl)-1,3-oxazol-4-yl]butyl]propanedioate；diethyl 2-[4-[2-(4-methylphenyl)-5-(trifluoromethyl)-1,3-oxazol-4-yl]butyl]propanedioate
• CAS: 1365270-46-7
• 化学式: C₂₂H₂₆F₃NO₅
• 分子量: 441.447
• InChiKey: HJHNBOGKTDSRDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  diethyl 2-{4-[2-(4-methylphenyl)-5-(trifluoromethyl)oxazol-4-yl]butyl}malonate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-(hydroxymethyl)-6-[2-(4-methylphenyl)-5-(trifluoromethyl)oxazol-4-yl]-1-hexanol
  参考文献：
  名称：

  Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists

  摘要：

  A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPAR alpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPAR alpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPAR alpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPAR alpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.007
• 作为产物：
  描述：

  4-(4-bromobutyl)-2-(4-methylphenyl)-5-(trifluoromethyl)oxazole 、 丙二酸二乙酯 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.25h， 生成 diethyl 2-{4-[2-(4-methylphenyl)-5-(trifluoromethyl)oxazol-4-yl]butyl}malonate
  参考文献：
  名称：

  Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists

  摘要：

  A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPAR alpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPAR alpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPAR alpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPAR alpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.007

文献信息

• Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists
  作者：Tetsuo Asaki、Tomiyoshi Aoki、Taisuke Hamamoto、Yukiteru Sugiyama、Shinji Ohmachi、Kenji Kuwabara、Kohji Murakami、Makoto Todo

  DOI：10.1016/j.bmc.2007.10.007

  日期：2008.1

  A series of 1,3-dioxane carboxylic acid derivatives was synthesized and evaluated for human PPAR transactivation activity. Structure-activity relationships on the phenyloxazole moiety of the lead compound 3 revealed that the introduction of small hydrophobic substituents at the 4-position of the terminal phenyl ring increased the PPAR alpha agonist activity, and that the oxazole heterocycle was essential to the maintenance of both potency and PPAR alpha subtype-selectivity. This investigation led to the identification of 14d (NS-220) and 14i as highly potent and selective human PPAR alpha agonists. In KK-A(y) type 2 diabetic mice, these compounds significantly lowered plasma triglyceride and very-low-density plus low-density lipoprotein cholesterol levels while simultaneously raising HDL cholesterol levels. Our results suggest that highly potent and subtype-selective PPAR alpha agonists will be promising drugs for the treatment of metabolic disorders in type 2 diabetes. (C) 2007 Elsevier Ltd. All rights reserved.